使用隐陡头菌素和生物标志物治疗实体肿瘤癌症的方法

• Format: Patent
• Language: Chinese
• Published: 25.02.2025
• Subjects: ACYCLIC OR CARBOCYCLIC COMPOUNDS; BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

本文公开了用于确定罹患实体肿瘤癌症的个体将受益于用隐陡头菌素治疗的可能性的方法。另外，还存在基于此类确定的治疗方法。在若干实施例中，标志物前列腺素还原酶1(PTGR1)、蛋白酪氨酸磷酸酶非受体14型(PTPN14)、天冬氨酸β-羟化酶(ASPH)与一种或多种基因一起或单独可用于增强或指导用隐陡头菌素治疗。在某些实施例中，蛋白质或基因可被表达或甲基化。 Methods for determining the likelihood that a subject suffering from a solid tumor cancer will benefit from treatment with an illudin are disclosed herein. Further, there are also methods for treatment based on such determination. In several embodiments, markers prostaglandin reductase 1 (PTGR1), Protein Tyrosine Phosphatase Non-Receptor Type 14 (PTPN14), Aspartate Beta- Hydroxylase (ASPH) together with one or more genes or alone may be used to enhance or guide treatment with an illudin. In certain embodiments, the protein or gene may be expressed or methylated.